Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep-Oct;36(5):384-392.
doi: 10.4103/lungindia.lungindia_475_18.

Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience

Abhijeet Singh  1 , Rajendra Prasad  1 , Ram Awadh Singh Kushwaha  1 , Rahul Srivastava  1 , Belur Hosmane Giridhar  1 , Viswesvaran Balasubramanian  2 , Amita Jain  3
Affiliations

Treatment outcome of multidrug-resistant tuberculosis with modified DOTS-plus strategy: A 2 years' experience

Abhijeet Singh et al. Lung India. 2019 Sep-Oct.

Abstract

Background: Multidrug-resistant tuberculosis (MDR-TB) is a global health problem with notoriously difficult and challenging treatment. This study determined treatment outcome in patients of MDR-TB with modified DOTS-Plus strategy.

Methods: Ninety-eight consecutive MDR-TB patients treated with standardized regimen according to modified DOTS-Plus strategy aligned to the existing national DOTS-Plus guidelines with relevant modifications proposed by Chennai consensus were analyzed prospectively. Treatment included monthly follow-up with clinical, radiological, and bacteriological assessment (sputum smear advised monthly till conversion then quarterly; culture for Mycobacterium tuberculosis at 0, 4, 6, 12, 18, and 24 months), ensuring adherence, intense health education, and monitoring of adverse events (AEs). Patients' outcome was considered as cure when at least two of the last three cultures (all three or last two) were negative and as failure when the same were positive.

Results: Favorable and unfavorable outcomes in this cohort were reported to be 71/98 (72.4%) and 27/98 (27.6%) (failure - 10 [10.2%], default - 7 [7.1%], and expiry - 10 [10.2%]), respectively. Sputum smear and culture conversion rate were 75/81 (92.5%) and 71/81 (87.7%), respectively. Major AEs were experienced in only 17.4% of patients.

Conclusions: MDR-TB can be cured successfully with modified DOTS-Plus strategy and requires much effort from both the patients and health-care workers. It can be an alternative model for treating MDR-TB patients in private sector.

Keywords: Drug resistant; individualized; programmatic management of multidrug-resistant tuberculosis; regimen; standardized; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
(a) Kaplan–Meier plot of the probability of survival among 98 multidrug-resistant tuberculosis patients from the time of diagnosis. (b) Probability of survival based on gender (P = 0.37, log-rank – Mantel–Cox test)
See this image and copyright information in PMC

References

    1. Tuberculosis Research Centre. Trends in initial drug resistance over three decades in a rural community in South India. Indian J Tuberc. 2003;50:75–86.
    1. Arnadottir T, Binkin N, Cegielski P, Espinal M, Farmen P, Goldfarb A, et al. WHO/CDS/TB/2000.279. Geneva: World Health Organization; 2000. Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multidrug Resistant Tuberculosis (MDR-TB)
    1. World Health Organization. Global Tuberculosis Report 2016. WHO/HTM/2016.13. Geneva: World Health Organization; 2016.
    1. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004;8:560–7. - PubMed
    1. Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-plus pilot experience in India: Results, constraints and issues. Int J Tuberc Lung Dis. 2009;13:976–81. - PubMed

LinkOut - more resources